MiMedx gains on reports of positive comments out of Craig Hallum; Epifix better than Grafix


MiMedx (MDXG +1.2%) moves up on some positive comments out of Craig Hallum this morning, saying that it thinks Epifix is better than Osiris Therapeutics (OSIR) Grafix.

Yesterday, OSIR soared on reports that its stem-cell based biosurgery product Grafix closed three times as many wounds as conventional treatment in a study of patients with a diabetic foot ulcer.

OSIR is taking a bit of a breather today, currently -12%.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs